A study of exercise endurance and lung hyperinflation in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

Study identifier:LAS-MD-CL26

ClinicalTrials.gov identifier:NCT00500318

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD

Medical condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 3

Healthy volunteers

No

Study drug

Aclidinium Bromide, Placebo

Sex

All

Actual Enrollment

181

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Jul 2007
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Sept 2010

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria